SINGAPORE, 14 APRIL 2022: Us2.ai, the Singapore-based medtech developers of FDA- cleared AI software that, for the first time ever, fully automates a complete echocardiography (heart ultrasound) report, today announced...
Pappas Ventures Names Pat Gage to Scientific Advisory Board
News | 07. 09. 2012
Pappas Ventures today announced the appointment of L. Patrick (Pat) Gage, PhD to the company's Scientific Advisory Board (SAB). Dr. Gage has extensive experience in the biotech and pharmaceutical industry, including previously-held senior positions at Hoffmann-La Roche, Genetics Institute and Wyeth (now Pfizer). Throughout his career, he oversaw the development of more than a dozen marketed biologics and vaccines, as well as several small molecule drugs.
Read the full press release here.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.